Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01932099
Other study ID # IP 011
Secondary ID G120160
Status Active, not recruiting
Phase Phase 2
First received August 20, 2013
Last updated October 27, 2016
Start date August 2013
Est. completion date December 2018

Study information

Verified date October 2016
Source Direct Flow Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

A study to assess the safety and effectiveness of the Direct Flow Medical aortic valve system. This is for people with severe aortic stenosis who are not well enough to undergo a surgical repair. The delivery of this device is done via the femoral artery.


Description:

The Direct Flow Medical Transcatheter Aortic Valve System is indicated for symptomatic patients who require replacement of their native aortic valve and have a predicted operative mortality or serious morbidity risk of equal or greater 50% at 30 days with surgical aortic valve replacement or are deemed unsuitable for surgery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date December 2018
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

1. The patient has severe senile degenerative aortic valve stenosis determined by resting or dobutamine stress echocardiogram and Doppler, or simultaneous pressure recordings at cardiac catheterization defined as: mean gradient >40 mmHg or peak jet velocity >4.0 m/s and an aortic valve area =0.8 cm2 or aortic valve area index =0.5 cm2/m2.

2. The patient has moderate to severe symptoms from aortic valve stenosis (NYHA Functional Class =III).

3. The patient must have a predicted risk of operative mortality or serious irreversible morbidity of >50% at 30 days, or be deemed not suitable for surgery for other reasons. This conclusion shall be based on consensus of one cardiologist and two cardiac surgeons at the investigational site after careful consideration of the patient's STS risk score and co-morbidities, and after at least one of the surgeons participating in the decision has personally examined the patient.

4. The patient been informed of the nature of the study, agrees to its provisions, is willing to comply with protocol-specified follow-up evaluations and has provided written informed consent, approved by the appropriate IRB.

Exclusion Criteria

1. Left ventricular ejection fraction (LVEF) <20% determined by resting echocardiogram

2. Patients with an acute MI within 30 days preceding the index procedure.

3. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the study procedure

4. Patients with impaired renal function (estimated Glomerular Filtration Rate [eGFR] <20cc/min, calculated from serum creatinine by the Cockcroft-Gault formula)

5. Patients with a platelet count of <50,000 cells/mm³ or a WBC < 1000 cells/mm³ within 7 days prior to index procedure.

6. Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion.

7. Patients who have received any organ transplant or are on a waiting list for any organ transplant.

8. Patients with known other medical illness (e.g. carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease) or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a life expectancy of less than one year, or expectation that patient will not improve despite treatment of aortic stenosis.

9. Patients with known hypersensitivity or contraindication to aspirin, heparin, clopidogrel/ticlopidine, and/or contrast sensitivity that cannot be adequately pre-medicated.

10. Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months.

11. Patients with an active gastrointestinal (GI) bleeding within the prior 6 months.

12. Patients presenting with hemodynamic instability or cardiogenic shock defined by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.

13. Patients who have a planned treatment with any other investigational device or procedure during the study period, or who are currently participating in an investigational drug or another device trial

14. Any planned surgical, percutaneous coronary or peripheral procedure to be performed prior to the 30 day follow-up from the TAVR procedure.

15. Untreated clinically significant coronary artery disease requiring revascularization

16. Trans-esophageal echocardiography (TEE) is contraindicated

17. Active endocarditis or sepsis within 6 months prior to the study procedure

18. Dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)

19. Congenital bicuspid or unicuspid valve determined by echocardiography

20. Prior aortic or mitral valve surgery or pre-existing prosthetic heart valve in any position

21. Native valve annulus diameter is <19mm or >26mm determined by the screening CT scan

22. Extreme asymmetrical calcification of the native aortic valve determined by the screening CT scan

23. Echocardiographic evidence of intra-cardiac mass, thrombus, vegetation, or spontaneous echo contrast in the left atrium

24. >3+ aortic regurgitation, mitral regurgitation or tricuspid regurgitation

25. Moderate to severe mitral stenosis

26. Thoracic aortic aneurysm (TAA) or abdominal aortic aneurysm (AAA) >5.0 cm

27. Presence of an endovascular stent graft for treatment of AAA or TAA 28 Hypertrophic obstructive cardiomyopathy

29. Patients with severe peripheral arterial disease that precludes sheath vascular access (e.g. luminal diameter less than 6.5 mm, severe obstructive calcification or severe tortuosity)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Transcatheter aortic valve replacement
Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.

Locations

Country Name City State
United States Northwestern Memorial Hospital Chicago Illinois
United States Cleveland CLinic Cleveland Ohio
United States Henry Ford Hospital Detroit Michigan
United States Columbia Univ. Medical Center New York New York
United States UC Davis Medical Center Sacramento California
United States Washington University Hospital St Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Direct Flow Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from all cause mortality/Device success Absence of procedural mortality AND correct positioning of a single prosthetic heart valve into the proper anatomic location AND Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient less than 20 mmHg or peak velocity less than 3m/s, AND no moderate or severe prosthetic valve regurgitation. 6 months post procedure Yes
Secondary Early Safety Early Safety: as a composite of
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute Kidney Injury - Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complications
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)
30 Days Yes
Secondary Clinical Efficacy Clinical Efficacy will be evaluated as a composite of:
All-cause mortality
All stroke (disabling and non-disabling)
Hospitalization for valve-related symptoms or worsening congestive heart failure† (including reporting of days hospitalized)
NYHA Class III or IV
Prosthetic heart valve dysfunction (mean aortic valve gradient =20 mm Hg, EOA =0.9-1.1 cm2‡ and/or DVI <0.35, AND/OR moderate or severe prosthetic valve regurgitation*)
6 months,and annually at 1 to 5 years No
Secondary Time-related Valve Safety Time-related valve safety will be evaluated as a composite of:
Structural valve deterioration:
Valve-related dysfunction (mean aortic valve gradient (mean aortic valve gradient =20 mm Hg, EOA =0.9-1.1 cm2[Depending on body surface area] and/or DVI <0.35, AND/OR moderate or severe prosthetic valve regurgitation [VARC defined])
Requiring repeat procedure (TAVR or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thromboembolic events (e.g., stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g., trauma)
30 days, 6 months and annually at 1 to 5 years Yes
Secondary Clinical Endpoints Individual Endpoints
All-cause mortality
Cardiovascular mortality
Non-cardiovascular mortality Myocardial Infarction
Peri-procedural MI (<72 hours after the index procedure)
Spontaneous MI (>72 hours after the index procedure) Neurological Events
Stroke
Ischemic stroke
Hemorrhagic stroke
Undetermined
Disabling Stroke
Non-disabling stroke
Transient ischemic attack Bleeding Complications
Life-threatening or disabling bleeding
Major bleeding
Minor bleeding Acute Kidney Injury (AKIN Classification)
Stage 1 acute kidney injury
Stage 2 acute kidney injury
Stage 3 acute kidney injury Vascular Complications
Major vascular complications
Minor vascular complications
Percutaneous closure device failure Prosthetic Valve Dysfunction
Prosthetic Aortic Valve Stenosis
Prosthesis-Patient Mismatch
Prosthetic Aortic Valve Regurgitation
30 days, 6 months and annually at 1 to 5 years. Yes
See also
  Status Clinical Trial Phase
Completed NCT03186339 - Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Completed NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease